MiRNA-based therapy for Lipid metabolism disorders: TGF-β1 inhibits the expression of IDH1 and lipid accumulation via up regulation of its target gene, 11/April/2015, 22.12

Small molecule-based Lifespan extension therapy: 17β-E2 (An estrogen derivative) increases life span via up regulation of its target gene BubR1, 11/April/2015, 22.03
April 11, 2015
Therapeutic insights into the treatment of Stress-induced heart failure: 5-aminoimidazole-4-carboxamide riboside (AICAR), an analog of AMP, protects against stress-induced heart failure via up regulation of SNX13, 11/April/2015, 22.22
April 11, 2015
Show all

A study from the CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Signaling Network, School of Life Sciences, University of Science & Technology of China, Hefei, Anhui 230027, China; Scientific and Educational Department, The second hospital of Anhui Medical University, Hefei, Anhui. 230061, China shows that “MiR-181a regulates lipid metabolism via IDH1.” This study was published in the 5 March  2015 issue of the Journal “Scientific Reports” by Prof Wu, Chu B, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based therapy for Lipid metabolism disorders: TGF-β1 inhibits the expression of IDH1 and lipid accumulation via up regulation of its target gene.

Significance:   Given that: (1) more than two billion adults are overweight globally; (2) 64% of US population is Overweight; and (3) the risk of death raises by 20-40% among overweight people, there is an urgent need to find an effective therapy for treating disorders associated with overweight.

This study suggests, for the first time, that TGF-β1, by increasing the expression of its target gene, it may inhibit the expression of IDH1 (Isocitrate dehydrogenase), a component of TCA cycle. Thereby, it may decrease and increase the expression of genes that promote lipid biosynthesis and β-oxidation, respectively. This, in turn, results in inhibition of lipid accumulation.  Thus, pharmacological formulations encompassing “TGF-β1 activators” may be used (1) to lower body weight; and (2) in the management of obesity disorders.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, MiRNA-based therapy for Lipid metabolism disorders: TGF-β1 inhibits the expression of IDH1 and lipid accumulation via up regulation of its target gene, 11/April/2015, 22.12, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Undisclosed information: How TGF-β1 inhibits the expression of IDH1

Comments are closed.